NASDAQ: SMMT - Summit Therapeutics Inc.

Yield per half year: +36.48%
Dividend yield: 0%
Sector: Healthcare

Share chart Summit Therapeutics Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Summit Therapeutics Inc.

Summit Therapeutics Inc., биофармацевтическая компания, занимается исследованиями и разработками в основном в области лечения онкологических заболеваний в США и Великобритании. Ассортимент продукции компании включает SMT-738, новый класс прецизионных антибиотиков для лечения, который находится на доклинической стадии для лечения инфекций с множественной лекарственной устойчивостью, которые в первую очередь включают инфекции Enterobacteriaceae, устойчивые к карбапенемам. Он имеет сотрудничество и лицензионное соглашение с Akeso, Inc.

more details
для исследования и разработки Ivonescimab (AK112) и SMT112, биспецифического антитела для иммунотерапии посредством блокады PD-1 с антиангиогенезом. Компания была основана в 2003 году и имеет штаб-квартиру в Кембридже, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2015-03-05
ISIN US86627T1088
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.summittxinc.com
Цена ао 25.85
Change price per day: 0% (25.85)
Change price per week: +5.99% (24.39)
Change price per month: +10.16% (23.465)
Change price per 3 month: +42.74% (18.11)
Change price per half year: +36.48% (18.94)
Change price per year: +981.59% (2.39)
Change price per 3 year: +2 700.65% (0.923)
Change price per 5 year: +683.33% (3.3)
Change price per year to date: +44.86% (17.845)
All parameters

Underestimation

Title Value Grade
P/S 790.91 1
P/BV 32.98 1
P/E 0 0
EV/EBITDA -59.78 0
Total: 1.75

Efficiency

Title Value Grade
ROA, % -63.78 0
ROE, % -90.76 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0339 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -98.82 0
Yield Ebitda, % 543.87 10
Yield EPS, % 2269.27 10
Total: 8
More

Institutions Volume Share, %
Blackrock Inc. 9759383 1.39
Vanguard Group Inc 7014982 1
Geode Capital Management, LLC 3085666 0.44
State Street Corporation 2456168 0.35
Northern Trust Corporation 1108089 0.16
Charles Schwab Investment Management, Inc. 953846 0.14
Morgan Stanley 704272 0.1
Steward Partners Investment Advisory, LLC 600000 0.09
Nuveen Asset Management, LLC 565624 0.08
Alps Advisors Inc. 532406 0.08

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 1.71443 426.34 0.8416
Principal Healthcare Innovators ETF 1.71443 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.04561 595.05 0.72598
iShares Morningstar Small-Cap Value ETF 0.04402 187.77 2.50476
iShares Morningstar Small-Cap ETF 0.04321 391.25 1.60498
0.71443.781.3



Head Job title Payment Year of birth
Mr. Robert W. Duggan Co-CEO & Executive Chairman N/A 1944 (81 year)
Prof. Dame Kay Davies DBE, FRS CBE Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor N/A 1951 (74 years)
Ms. Abby Guzman Murphy Head of Human Resources N/A
Ms. Divya Chari Head of Global Clinical Operations N/A 1968 (57 years)
Mr. Dave Gancarz Chief Business & Strategy Officer N/A
Dr. Mahkam Zanganeh D.D.S., M.B.A. Co-CEO, President & Director 657.81k 1970 (55 years)
Mr. Manmeet Singh Soni COO, CFO & Director 591.5k 1978 (47 years)
Dr. Betty Y. Chang Ph.D. Head of Research, Oncology & Inflammation N/A
Mr. Bhaskar Anand Chief Accounting Officer & Head of Finance 1978 (47 years)
Dr. Fong Clow Chief Biometrics Officer

Address: United States, Cambridge. MA, 2882 Sand Hill Road. Suite 106 - open in Google maps, open in Yandex maps
Website: https://www.summittxinc.com